News and Announcements
Analytica (ASX: ALT) Receives $720k Placement Funds, Release PeriCoach V3 & Appoints New Director
- Published August 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach System and AutoStart Infusion system has recently released its Quarterly Cashflow report for the period ending June 30, 2017.
KEY TAKEAWAYS:
- Appointment Dr Peter B.Corr director
- Release of PeriCoach vision 3 (V3) device
- PeriCoach structured exercise program released
- Cash balance as of 30th June, $1,212k
- Share placement approved by shareholders in April for $720k
- Investigating AutoStart infusion system use-age for Home Based Hospital care
- Updated clinical guidelines for surgical management of Stress Urinary Incontinence
- Analysis of V2 clinical trial; superior results of quality of life improvements, sexual satisfaction scores and improved continence among PeriCoach users.
- PeriCoach patent issue for Australia.
PeriCoach is a regulated medical device, built as a data collection system. The system provides opportunity for new insights into management and motivation of the conservative treatment pathway for female pelvic floor disorders. The core capability is the driver for the pursuit of clinical evidence in the forms of studies and surveys as well as development of enhanced functionality of the PeriCoach system.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
